Welcome to the homepage of AIHTA!
AIHTA is an acadmic non-profit institute. At our website we wish to present our research and give support for health care decision-making. Here all of our reports are available for free. For further information please contact the AIHTA team.
We are pleased to introduce you three new Fact Sheets.
Fact Sheet No. 131 (May 2023)
Pirtobrutinib (JaypircaTM) as monotherapy for the treatment of relapsed or refractory (R/R) mantle cell lymphoma (MCL)
Fact Sheet No. 132 (May 2023)
Futibatinib (Lytgobi®) for the treatment of locally advanced or metastatic cholangiocarcinoma
We are pleased to introduce you two new Fact Sheets.
Fact Sheet No. 134 (May 2023)
Piflufolastat (18F) (Pylclari®) for the diagnosis of prostate cancer
We are pleased to introduce you one new Fact Sheets.
Fact Sheet No. 129 (April 2023)
Lisocabtagene maraleucel (Breyanzi®) for the treatment of diffuse large B-cell lymphoma (DLBCL), high grade B cell lymphoma (HGBCL), primary mediastinal large B-cell lymphoma (PMBCL) and follicular lymphoma grade 3B (FL3B)
As patient initiatives expand their activities and continue to professionalise, their need for financial resources, which often gets bankrolled by pharma-ceutical companies, increases accordingly. To make these financial transactions more transparent, the pharmaceutical industry responded with volun-tary disclosure commitments. AIHTA (then still as LBI-HTA) systematical-ly analysed the content of these voluntary disclosures of sponsorship for pa-tient initiatives by members of the Association of Austria’s Pharmaceutical Industry (PHARMIG - Verband der pharmazeutischen Industrie Österreichs) for the first time in 2014 and aims to carry out regular and consistent moni-toring of these payments. The present fifth update systematically researched the extent of financial support to patient initiatives disclosed by member companies of PHARMIG for the fiscal year of 2021.
Oral and parenteral preexposure prophylaxis (PrEP) to prevent HIV in people at risk: a systematic review of clinical effectiveness and safety with assessment of organisational, economic, patients/social, ethical and legal elements
Preexposure prophylaxis (PrEP) is an antiretroviral therapy-based HIV prevention strategy to prevent HIV infection in people who have not been infected with the virus but are at high risk of infection. The report aimed to provide an update evidence synthesis based on a systematic literature search regarding the effectiveness and safety of in the EU and/ or US approved oral and parenteral PrEP pharmaceutical to prevent HIV infection in populations at risk. Additionally, the report addressed organisational, economic, patient/social, ethical and legal aspects to support evidence-based decision-making process on PrEP in Austria.
This report is based on that of the LBI-HTA of 2015 and the updates of 2018 and 2020. Various guideline databases and policies were searched to identify the recommended oncological indications for the use of PET/PET-CT applications. In addition to guideline databases, recommendations and non-recommendations from professional societies were considered.
The guideline search identified a total of 122 recommendations regarding the use of PET. The majority of the recommendations (n=112) resulted from the guideline search and database search of national professional societies. The search in supranational professional societies resulted in 10 recommendations. A further 36 recommendations were directed against the use of PET ("inappropriate" cancer indications).
The overall recommendations of the present 2023 update (as in the previous year's 2015 & 2018 reports, as well as the 2020 update) indicate little benefit from PET as a primary or standard diagnostic (not least because of radiation exposure). The summarised evidence from guidelines can be used as a guideline for investment decisions.
We are pleased to introduce you four new Fact Sheets.
Fact Sheet No. 125 (April 2023)
Niraparib/abiraterone acetate (Akeega®) for the treatment of metastatic castration-resistant prostate cancer (mCRPC)
Fact Sheet No. 127 (April 2023)
Ivosidenib (Tibsovo®) monotherapy for the treatment of locally advanced or metastatic cholangiocarcinoma